
August 13, 2020

Listing Department
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400051

Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated August 13, 2020 titled “Zydus launches Remdac™ (Remdesivir) for the treatment of COVID 19 in India”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors' at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zy+us launches Remdac™ (Remdesivir) for the treatment of COVID 19 in India

- *Priced at Rs. 2800 per 100 mg vial; Complete backward integration makes Remdac™ the most economical Remdesivir brand in India.*

Ahmedabad, India, August 13, 2020

Zy+us, a leading discovery-based, global pharmaceutical company today announced that it has launched Remdesivir under the brand name Remdac™ in the Indian market. Priced at Rs. 2800 for a 100 mg lyophilized injection, Remdac™ is the most economical Remdesivir brand in India. The drug will be made available across India through the group's strong distribution chain reaching out to Government and private hospitals treating COVID patients.

“Remdac™ is the most affordable drug as we would like to enable patients to have access to this critical drug in the treatment of COVID 19”, said Dr. Sharvil Patel, the Managing Director of Cadila Healthcare Limited. “Through the course of this pandemic, our efforts have been focused on supporting people in this healthcare crisis, whether it is through developing vaccines, ramping up production and distribution of critical drugs and therapies, making diagnostic tests available or exploring new treatment options”, he added.

In June 2020, Zy+us entered into a non-exclusive agreement with Gilead Sciences Inc., to manufacture and sell Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of COVID 19. The API for the drug has been developed and manufactured at the group's API manufacturing facilities in Gujarat.

Remdac™ marks yet another step in the group's efforts to the fight the pandemic with vaccines, therapeutics and diagnostics. The group had ramped up production of HCQ and Dexamethasone when required and is also conducting clinical trials with Pegylated Interferon Alpha 2b and Desidustat for the treatment and management of COVID 19. Nearly 3 lakh COVID Kavach Elisa diagnostic tests have been supplied for surveillance. The group's plasmid DNA vaccine ZyCov-D is now in Phase II of the Adaptive Phase I&II clinical trials.

About Zy+us

Zy+us Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs nearly 25,000 people worldwide, including 1,400 scientists engaged in R & D, and is dedicated to creating healthier communities globally.

www.zyduscadila.com

For further information please contact :
The Corporate Communications Department

Cadila Healthcare Limited

Regd. Office : 'Zy+us Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878